In conclusion, our data suggest that plasma IL-17 and TH17 cytokines may be a valuable baseline biomarker for response prediction and patient stratification in melanoma, specifically to predict a potential benefit of adding anti-CTLA-4 to anti-PD-1 antibodies upfront to therapy. Here, PDCD1 is linked to melanoma.